Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
PNT2002 / POINT Biopharma, Lantheus
Lutetium-177 PNT2002 for Prostate Cancer | Open Medscience
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
(R)-Zadavotide guraxetan ((R)-PSMA I&T) | PSMA Inhibitor | MedChemExpress
ESMO 22: Results of the 177Lu-PNT2002 SPLASH Trial | GU Oncology Now
Frontiers | Initial clinical experience with [177Lu]Lu-PNT2002 ...
ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate ...
Chemical structures of 177 Lu-PSMA-617 and 177 Lu-PSMA I&T. | Download ...
Dose‐adapted stereotactic body radiation therapy based on the response ...
[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer ...
A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu ...
作为靶向前列腺特异性膜抗原的治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA的制作方法
177Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with ...
PSMA-Targeting Radioligand Therapy in Prostate Cancer | Published in ...
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC | Targeted ...
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate ...
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC
[Lu-177]-PNT2002 for Prostate Cancer Clinical Trial 2023 | Power
More Than Meets the Eye: Scientific Rationale behind Molecular Imaging ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC | Urology Times
177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical ...
ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific ...
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
slide16
slide15
(PDF) Initial clinical experience with [Lu]Lu-PNT2002 radioligand ...
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following ...
Prostate Cancer Molecular Imaging and Therapy in MIRROR and 177Lu ...
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA ...
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic ...
【速递】礼来收购PSMA核药变故？从市场竞争角度分析医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
POINT生物制药在PNT2002的3期SPLASH试验中完成随机化 - 中国核技术网
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled ...
Study on Treating Metastatic Castration-Resistant Prostate Cancer with ...
Planar scintigraphic images of ²⁰³Pb-labelled compounds in C4-2 ...
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial ...
Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression ...
New therapy delays progression of recurrent prostate cancer | UCLA Health
AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
slide12
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
Frontiers | 177Lu-labeled PSMA targeting therapeutic with optimized ...
PSMA and Beyond 2025: Overview of Clinical Trials of PSMA RLT in 2025
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
slide13
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate ...
Peptide-Radionuclide Conjugates: Interpretation of FDA Approved Drugs ...
核药赛道探险者：POINT Biopharma，扎根高端用药布局_摩熵医药(原药融云)
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment ...
Matched-Pair Analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in ...
POINT Biopharma Confirms No Disruptions to the Manufacturing and ...
ESMO 2024: Will Theranostics Become Standard of Care?
Quality Assurance Investigations and Impurity Characterization during ...
Characterization of Non-Specific Uptake and Retention Mechanisms of ...
[Figure, Treatment mechanism of 177-Lu-PSMA Madhusudan Vyas ...
SNMMI 2025: A Dose-Escalation Study of the Novel PSMA-Targeting Drug ...
[PDF] 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted ...
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company on ...
ESMO 2025: 177Lutetium-PSMA Therapy Neoadjuvant to Stereotactic ...
Frontiers | Quantitative imaging for 177Lu-PSMA treatment response ...
C6H6 lewis structure, molecular geometry, bond angle, hybridization
ESMO 2025: Discussant – PR.21 and LUNAR Trials
:%0A%0A[Lu-177]-PNT2002%20for%20Prostate%20Cancer.png?md=1)
